AI assistant
Edwards Lifesciences Corp — Director's Dealing 2021
Apr 2, 2021
30042_dirs_2021-04-01_fdb1798e-dfef-4588-83d7-f1df78c44eea.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Edwards Lifesciences Corp (EW)
CIK: 0001099800
Period of Report: 2021-04-01
Reporting Person: Lemercier Jean-Luc M (CVP, EMEA, Canada, Latin Amer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-04-01 | Common Stock | M | 13020.0000 | $13.9800 | Acquired | 152561.1380 | Direct |
| 2021-04-01 | Common Stock | S | 13020.0000 | $83.6608 | Disposed | 139541.1380 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-04-01 | Employee Stock Option (Right to Acquire) | $13.9800 | M | 13020.0000 | Disposed | 2021-05-07 | Common Stock (13020.0000) | Direct |
Footnotes
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 23, 2020.
F2: This transaction was executed in multiple trades at prices ranging from $83.1600 to $84.0000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.